ABSTRACT
OBJECTIVE:To observe therapeutic efficacy and safety of cinobufacini capsules combined with paclitaxel and cisplatin in the treatment of middle and advanced cervical cancer.METHODS:A total of 92 patients with middle and advanced cervical cancer were randomly divided into observation group (46 cases) and control group (46 cases).Both groups received pelvic intensity-modulated radiotherapy (IMRT)+interstitial brachytherapy.Control group was additionally given Paclitaxel injection 135 mg/m2,d1+Cisplatin injection 75 mg/m2,d1,21 d as a treatment course,and received chemotherapy for 2 cycles since the fnrst day of radiotherapy.Observation group was additionally given Cinobufacini capsules 0.5 g orally since the first day of radiotherapy,3 times a day,until the end of radiotherapy.Clinical efficacies as well as platelet count,KPS score,body weight,pain relief and the recovery of platelet abnormality were observed in 2 groups,and the occurrence of toxic reaction was recorded.RESULTS:The complete remission rate,the rate of platelet count abnormality recovery as well as remission rate and total remission rate of pain after 3 weeks of treatment in observation group were significantly higher than control group,with statistical significance (P＜0.05).There was no statistical significance in the total response rate and remission rate after 4,5 weeks of treatment between 2 groups (P＞0.05).After treatment,platelet count of 2 groups were significantly lower than before,and the observation group was significantly lower than the control group;KPS score of 2 groups and body weight of observation group were significantly higher than before treatment;body weight of control group was significantly lower than before,and the observation group was significantly higher than the control group,with statistical significance (P＜0.05).The incidence of grade Ⅲ-Ⅳ neutropenia,nausea and vomiting,grade Ⅰ-Ⅱ diarrhea in observation group were significantly lower than control group,with statistical significance (P＜0.05).CONCLUSIONS:Based on conventional treatment,cinobufacini capsules combined with paclitaxel and cisplatin show significantly therapeutic efficacy for middle and advanced cervical cancer,improve blood hypercoagulation and survival quality,relieve pain and reduce the occurrence of toxic reaction.
ABSTRACT
OBJECTIVE:To observe the clinical efficacy and safety of Cinobufacini capsule in the treatment of tumor patients with intractable hiccup. METHODS:120 tumor patients with intractable hiccup were randomly divided into observation group(60 cases) and control group (60 cases) according to the random number table. Control group received conventional treatment,treat-ment of primary disease,and the basic treatment of Methoxy metoclopramide tablets 10 mg,tid and intraorbital pressure on neural network method;observation group additionally received Cinobufacini capsule,2 capsules once,3 times a day. 1-week was regard-ed as a treatment course,and it lasted 4 courses. Clinical efficacy,Karnofsky functional status(KPS)score and disappearance time of hiccup were observed,and the incidence of adverse reactions was evaluated by TESS scale. RESULTS:After treatment,the to-tal effective rate in observation group was significantly higher than control group,the disappearance time of hiccup and TESS score were significantly shorter than control group,the differences were statistically significant(P<0.05). Before treatment,there was no significant difference in the KPS score;after treatment,the KPS score in 2 groups was significant higher than before,and observa-tion group was higher than control group,the difference was statistically significant(P<0.05). CONCLUSIONS:Both efficacy and safety of Cinobufacini capsule in the treatment of intractable hiccup are good,and it can shorten hiccup duration.
ABSTRACT
OBJECTIVE:To observe clinical efficacy and toxic reaction of bronchial artery infusion(BAI)chemotherapy com-bined with Cinobufacini capsule in the treatment of advanced non-small cell lung cancer(NSCLC). METHODS:A total of 126 cas-es of advanced NSCLC diagnosed in stage Ⅲb-Ⅳ were randomly divided into observation and control group,63 cases in each group. Both of them were treated by BAI with taxotere/cisplatin(TP regimen),once every three weeks for a cycle,a total of 5 cy-cles;observation group was additionally given Cinobufacini capsule 500 mg/time,three times a day,on the basis of BAI chemo-therapy,for 15 weeks. Clinical efficacy,KPS,survival rate and toxic reaction of 2 groups were observed. RESULTS:The total ef-fective rate(82.54%)of observation group was better than that(63.49%)of control group,with statistical significance(P<0.05). KPS score of observation group was significantly better than that of control group,with statistical significance (P<0.05). 1-year survival rate of observation group and control group were 65.08% and 30.15%,2-year survival rate of them were 19.05% and 4.76%,with statistical significance(P<0.05). Adverse reactions of two groups was mainly marrow suppression and gastrointesti-nal reaction,marrow suppression degree and the incidence of nausea and vomiting in observation group was lighter than control group,with statistical significance (P<0.05). CONCLUSIONS:BAI combined with Cinobufacini capsule in the treatment of ad-vanced NSCLC can improve short-term curative effect and long-term survival rate,and can improve the survival quality with little toxic effect.